LONDON Macrophage Pharma Ltd. has raised £9 million (US$10.9 million) in a series A to commercialize a small-molecule immuno-oncology technology originally developed by chromatin biology specialist, Chroma Therapeutics Ltd.
The round was led by the Cancer Research UK Technology Pioneer Fund (CPF), which formed Macrophage after licensing the Chroma assets in October 2013. Joining CPF in the round were Novo Seeds, the corporate venture arm of Novo A/S, and Dutch VC Aglaia Biomedical Ventures.
The esterase sensitive motif (ESM) technology licensed from Chroma allows chemical motifs to be attached to small-molecule drugs, enhancing delivery to specific intracellular targets. Once inside the